Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription 08.09.2025 1 Acta Neurol Belg 1 Acta Psychiatr Scand 6 Am J Psychiatry 2 Br J Psychiatry 1 Can J Psychiatry 2 J Clin Psychopharmacol 2 Mol Psychiatry 1 Pharmacopsychiatry 1 PLoS Comput Biol 1 Psychol Med 7 Schizophr Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Neurol Belg

1. AGUDA A, Mavroudis I
   Risk of psychosis following mild traumatic brain injury: a systematic review and meta-analysis.
   Acta Neurol Belg. 2025 Sep 2. doi: 10.1007/s13760-025-02883.
   PubMed         Abstract available
   
   

   
   Acta Psychiatr Scand

2. PEYROVIAN B, Palaniyappan L, Kolivakis TT, Margolese HC, et al
   Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials.
   Acta Psychiatr Scand. 2025 Sep 4. doi: 10.1111/acps.70034.
   PubMed         Abstract available
   
   

   
   Am J Psychiatry

3. KALIN NH
   Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder.
   Am J Psychiatry. 2025;182:797-800.
   PubMed        
   
   
4. HORAN WP, Harvey PD, Brannan SK
   Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon.
   Am J Psychiatry. 2025;182:878-879.
   PubMed        
   
   
5. CASSIDY C, Wang Y, Abi-Dargham A
   Forging a Role for Iron in the Dopamine Dysfunction of Schizophrenia.
   Am J Psychiatry. 2025;182:804-806.
   PubMed        
   
   
6. VANO LJ, McCutcheon RA, Sedlacik J, Kaar SJ, et al
   Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.
   Am J Psychiatry. 2025;182:830-839.
   PubMed         Abstract available
   
   
7. TANDON R
   Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia?
   Am J Psychiatry. 2025;182:878.
   PubMed        
   
   
8. ANGLIN DM, Olfson M, van der Ven E, Oh H, et al
   Neighborhood Social Vulnerability and Racial Disparities in Schizophrenia Spectrum Disorder Prevalence.
   Am J Psychiatry. 2025;182:850-860.
   PubMed         Abstract available
   
   

   
   Br J Psychiatry

9. WILKINSON H, Johns LC, Batchelor R, Lau-Zhu A, et al
   Cognitive behavioural therapy for sleep problems in psychosis: systematic review of effectiveness and acceptability - CORRIGENDUM.
   Br J Psychiatry. 2025 Sep 4:1. doi: 10.1192/bjp.2025.10420.
   PubMed        
   
   
10. PRIES LK, Prachason T, Arias-Magnasco A, Lin BD, et al
    Impact of puberty timing, status and oestradiol on psychotic experiences in the context of exposomic and genomic vulnerability to schizophrenia in female adolescents: longitudinal ABCD study.
    Br J Psychiatry. 2025 Sep 3:1-8. doi: 10.1192/bjp.2025.
    PubMed         Abstract available
    
    

    
    Can J Psychiatry

11. LIU S, Tang S, Tan Y, Xiang B, et al
    Influence of Virtual Reality on Negative Symptoms and Quality of Life of Patients With Schizophrenia: A Meta-Analysis: Influence de la realite virtuelle sur les symptomes negatifs et la qualite de vie des patients atteints de schizophrenie : une meta-
    Can J Psychiatry. 2025 Sep 2:7067437251372186. doi: 10.1177/07067437251372186.
    PubMed         Abstract available
    
    

    
    J Clin Psychopharmacol

12. DA SILVA TM, Vianna DRB, Meulman J, Turncliff R, et al
    Multicenter Bioavailability Study of Long-Acting Paliperidone in Patients With Schizophrenia or Schizoaffective Disorder.
    J Clin Psychopharmacol. 2025 Sep 4. doi: 10.1097/JCP.0000000000002078.
    PubMed         Abstract available
    
    
13. PETERS SJ, Staninska A, Lehmann I, Gouzoulis-Mayfrank E, et al
    Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.
    J Clin Psychopharmacol. 2025 Sep 5. doi: 10.1097/JCP.0000000000002079.
    PubMed         Abstract available
    
    

    
    Mol Psychiatry

14. VANO LJ, McCutcheon RA, Sedlacik J, Rutigliano G, et al
    The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study.
    Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03195.
    PubMed         Abstract available
    
    
15. AHIRWAR LK, Blackburn SL, McBride DW, T PK, et al
    Reviewing vascular influences on neuronal migration, cortical development, and neurodevelopmental disorders: focus on autism, ADHD and schizophrenia.
    Mol Psychiatry. 2025 Sep 2. doi: 10.1038/s41380-025-03200.
    PubMed         Abstract available
    
    

    
    Pharmacopsychiatry

16. CENDROS M, Catalan R, Torra M, Penades R, et al
    Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments.
    Pharmacopsychiatry. 2025;58:205-215.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

17. KSIAZEK K, Masarczyk W, Glomb P, Romaszewski M, et al
    Deep learning approach for automatic assessment of schizophrenia and bipolar disorder in patients using R-R intervals.
    PLoS Comput Biol. 2025;21:e1012983.
    PubMed         Abstract available
    
    

    
    Psychol Med

18. ODUOLA S, Pathan S, Hodgekins J, Teague B, et al
    Ethnic disparities, clinical and pathways to care characteristics associated with the offer, uptake, and type of psychological therapy during first-episode psychosis: examining the role of early intervention for psychosis.
    Psychol Med. 2025;55:e262.
    PubMed         Abstract available
    
    

    
    Schizophr Res

19. HSU JW, Chen LC, Lin WC, Bai YM, et al
    Reduced levels of vascular endothelial growth factor were associated with psychopathology in youth with first-episode schizophrenia.
    Schizophr Res. 2025;284:269-274.
    PubMed         Abstract available
    
    
20. NKIRE N, Kingston T, Kinsella A, Russell V, et al
    Prediction of long-term outcome by duration of the psychosis prodrome: Mixed effects models reveal continuity across 7 years but variation across quartile splits.
    Schizophr Res. 2025;284:263-268.
    PubMed         Abstract available
    
    
21. HOTER ISHAY G, Roe D
    Patterns of service utilization and its relation to outcome in a first-episode psychosis program.
    Schizophr Res. 2025;284:256-262.
    PubMed         Abstract available
    
    
22. WATERS Z, Ohan JL, Perry Y, Baird S, et al
    Perceived stigma and self-stigma in young people at ultra-high risk for psychosis: Associations with identity-related, psychological and functional outcomes.
    Schizophr Res. 2025;284:248-255.
    PubMed         Abstract available
    
    
23. INO H, Akabayashi A, Takimoto Y, Mori K, et al
    Effect of social resources on readmission prevention and the influence of informal coercion in acute schizophrenia: a retrospective quasi-experimental cohort study.
    Schizophr Res. 2025;285:1-10.
    PubMed         Abstract available
    
    
24. SANJARI MOGHADDAM H, Aarabi MH, Kiani I, Cattarinussi G, et al
    Microstructural alterations of the corpus callosum in affective and non-affective early psychosis: A diffusion magnetic resonance imaging study.
    Schizophr Res. 2025;284:237-247.
    PubMed         Abstract available
    
    
25. NASHASHIBI L, Harlev D, Grinapol S, Karny T, et al
    Ethnic bias in risk assessment of patients with early-onset first episode psychosis.
    Schizophr Res. 2025;284:231-236.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.